Mild cognitive disorder. Mild cognitive impairment, so stated
Conditions
Interventions
Intervention 1: Individuals in the cinnamon group will take Synabiotic capsules containing 500 mg of cinnamon orally twice a day for three months. These capsules will be supplied by Sagepad Darou Comp
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Mild cognitive impairment (MCI) patinets 60 years old or older
Exclusion criteria
Exclusion criteria: Having liver disease and liver failure Presence of major heart or brain disease such as acute heart or brain attack Having a history of active stomach or duodenal ulcer in the last 3 months Any history of major psychiatric disorder including psychosis, major depression, bipolar disorder, or alcohol abuse A history of head injury with loss of consciousness Having a history of active malignancy or cancer in the last 24 months Any history of seizures Mental retardation and Down syndrome Presence of severe asthma or chronic obstructive pulmonary disease Taking cholinesterase inhibitors or memantine in the last 1 month Simultaneous use of drugs with the possibility of interfering with cognition, such as anticholinergic drugs, anticonvulsants, antiparkinsonian stimulants, cholinergic antipsychotic drugs, painkillers, antidepressants, or anti-anxiety drugs. Pregnancy or breastfeeding History of known allergy to cinnamon or its ingredients The presence of acute or uncontrolled diabetes in the patient The presence of kidney disease and kidney failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in BACE1 level. Timepoint: BACE1 level measurement at the beginning and end of the intervention (day 0 and day 90). Method of measurement: BACE1 serum level using ELISA kit.;Changes in MMSE score. Timepoint: MMSE score measurement at the beginning and end of the intervention (day 0 and day 90). Method of measurement: MMSE questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count (CBC). Timepoint: before and after the intervention (on 0 and 90 days). Method of measurement: using the relevant laboratory kits.;Serum levels of liver function tests: ALT, AST, bilirubin total and direct. Timepoint: before and after the intervention (on 0 and 90 days). Method of measurement: using the relevant laboratory kits.;Serum levels of Kidney function tests: Creatinine, Urea, BUN. Timepoint: before and after the intervention (on 0 and 90 days). Method of measurement: using the relevant laboratory kits.;Serum levels of lipid profile tests: Triglyceride, cholesterol, HDL,LDL. Timepoint: before and after the intervention (on 0 and 90 days). Method of measurement: using the relevant laboratory kits.;Serum levels of oxidant-antioxidant tests: SOD,MDA, catalase, glutathione, NOx. Timepoint: before and after the intervention (on 0 and 90 days). Method of measurement: using the relevant laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Nakhaee
Birjand University of Medical Sciences
Outcome results
None listed